Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha ® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018

Additional Analyses of Real-World Data Will Explore Treatment Utilization and Understanding of Treatment Goals in Patients at High Risk for Cardiovascular Events THOUSAND OAKS, Calif., Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER-1 study, evaluating the long-term safety and efficacy of Repatha® (evolocumab) in patients with hypercholesterolemia for up to five years. Additional abstracts to be presented include a sub-analysis of the Repatha cardiovascular outcomes study (FOURIER), investigating the effects of triglycerides on cardiovascular risk in patients with established c...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news